Rani Wins 180 More Days To Restore Nasdaq Compliance, With A Reverse Split Possible
Its Class A shares transferred to the Nasdaq Capital Market Thursday, keeping the RANI ticker.
Rani Therapeutics, which develops swallowable capsules to deliver biologic medicines, won 180 more days Tuesday to meet Nasdaq's minimum bid-price requirement. In an SEC filing Thursday, Rani said it had told Nasdaq a reverse stock split could be used if necessary to fix the deficiency.
A New Deadline, Same Price Test
Rani now has until May 10, 2027 to regain compliance. Its initial 180-calendar-day window ended Monday, and its Class A shares transferred from the Nasdaq Global Market to the Nasdaq Capital Market at Thursday's opening, retaining the RANI ticker.
The listing problem began with a May 11 notice in 2026, after Rani's closing bid price had been below $1.00 for 30 consecutive business days.
Nasdaq granted the extension because Rani satisfied the applicable market-value threshold for publicly held shares and the Capital Market's other initial-listing requirements apart from the bid-price test. Rani also gave written notice that it intends to remedy the deficiency.
To qualify, the shares must post a closing bid of at least $1.00 for a minimum of 10 consecutive business days during the extension. Nasdaq can require a longer stretch, generally no more than 20 consecutive business days.
Capsules Still In Development
Rani's RaniPill platform aims to deliver antibodies and proteins through the intestinal wall, replacing conventional injections. It includes capsules for solid and liquid drugs, with development programs focused on obesity, inflammatory conditions and hemophilia.
The company has no products approved for sale and has generated no commercial product sales revenue. Its partners include Chugai Pharmaceutical, which paid Rani $10 million upfront under an October 2025 collaboration and license agreement.
Rani conducts clinical studies in Australia and handles capsule design, prototyping and pilot manufacturing in-house. Alongside that development work, it plans to monitor its closing bid price and assess options for restoring listing compliance.
A reverse stock split would combine existing shares into fewer shares. Rani identified that option as a possible remedy if needed; the extension gives it additional time to satisfy Nasdaq's price test.
Nasdaq will confirm compliance in writing and close the matter if Rani meets the requirement. Rani cautioned that regaining compliance during the extension is not assured.